0
Orphan Designations
2
FDA Approvals
Latest: FILSUVEZ (2023)
1
Active Trials
200 recruiting
1
Rare Diseases
across 2 areas
1
News (30d)
Amryt Pharmaceuticals DAC is a company with 0 orphan drug designations across 1 rare disease, including 2 FDA-approved therapies. Active clinical trials in 1 indication. 5 active policy bills affect their portfolio. 1 news article in the past 30 days.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| diabetes mellitus | - | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
1
avg importance: 70
5
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
1
avg importance: 70
5
affecting portfolio